Viewing Study NCT04176185



Ignite Creation Date: 2024-05-06 @ 1:59 PM
Last Modification Date: 2024-10-26 @ 1:23 PM
Study NCT ID: NCT04176185
Status: TERMINATED
Last Update Posted: 2022-06-30
First Post: 2019-10-25

Brief Title: A Research Study in Chinese People With Allergy to House Dust Mites Using an Environmental Exposure Chamber
Sponsor: ALK-Abelló AS
Organization: ALK-Abelló AS

Study Overview

Official Title: A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite HDM Sublingual Immunotherapy SLIT-Tablet in Adult Chinese Subjects With HDM Allergic RhinitisRhinoconjunctivitis Using an Environmental Exposure Chamber
Status: TERMINATED
Status Verified Date: 2021-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: COVID-19
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: QUEST
Brief Summary: This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR The efficacy is evaluated using an environmental exposure chamber EEC Subjects will be randomised to receive treatment with HDM SLIT-tablet and placebo 11
Detailed Description: This trial is a 24 weeks randomised parallel-group double-blind placebo-controlled phase III trial Approximately 202 subjects will be randomised 11 to receive treatment with HDM SLIT-tablet or placebo The trial will be conducted in China with subjects recruited and treated in China Two EEC assessments baseline and end of treatment will take place at a validated EEC facility in Austria

The primary objective is to demonstrate the efficacy of the HDM SLIT-tablet 12 SQ-HDM once daily compared to placebo in the treatment of HDM AR nasal symptom determined during the EEC session at week 24

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None